Cargando…

Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine

BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to v...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Mian, Dou, Xiaowen, Zhang, Xiuming, Yan, Mingchen, Xiong, Dan, Jiang, Ruiwei, Ou, Tong, Tang, Aifa, Yu, Xiqiu, Zhu, Feiqi, Li, Weiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397116/
https://www.ncbi.nlm.nih.gov/pubmed/36016943
http://dx.doi.org/10.3389/fimmu.2022.938378
_version_ 1784772064186466304
author Peng, Mian
Dou, Xiaowen
Zhang, Xiuming
Yan, Mingchen
Xiong, Dan
Jiang, Ruiwei
Ou, Tong
Tang, Aifa
Yu, Xiqiu
Zhu, Feiqi
Li, Weiqin
author_facet Peng, Mian
Dou, Xiaowen
Zhang, Xiuming
Yan, Mingchen
Xiong, Dan
Jiang, Ruiwei
Ou, Tong
Tang, Aifa
Yu, Xiqiu
Zhu, Feiqi
Li, Weiqin
author_sort Peng, Mian
collection PubMed
description BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to vaccination with three doses of inactivated SARS-CoV-2 vaccine were followed in a cohort of 37 healthy adults (18–59 years old). Blood samples were collected at multiple time points and submitted to peptide array, machine learning modeling, and sequence alignment analyses, the results of which were used to generate vaccine-induced antibody-binding region (VIABR) immunosignatures (Registration number: ChiCTR2200058571). RESULTS: Antibody spectrum signals showed vaccination stimulated antibody production. Sequence alignment analyses revealed that a third vaccine dose generated a new highly represented VIABR near the A570D mutation, and the whole process of inoculation enhanced the VIABR near the N501Y mutation. In addition, the antigen conformational epitopes varied between short- and long-term samples. The amino acids with the highest scores in the short-term samples were distributed primarily in the receptor binding domain (RBD) and N-terminal domain regions of spike (S) protein, while in the long-term samples (12 weeks after the 2(nd) dose), some new conformational epitopes (CEs) were localized to crevices within the head of the S protein trimer. CONCLUSION: Protective antigenic epitopes were revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine inoculation. A third dose results in a new top-10 VIABR near the A570D mutation site of S protein, and the whole process of inoculation enhanced the VIABR near the N501Y mutation, thus potentially providing protection from strains that have gained invasion and immune escape abilities through these mutation.
format Online
Article
Text
id pubmed-9397116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93971162022-08-24 Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine Peng, Mian Dou, Xiaowen Zhang, Xiuming Yan, Mingchen Xiong, Dan Jiang, Ruiwei Ou, Tong Tang, Aifa Yu, Xiqiu Zhu, Feiqi Li, Weiqin Front Immunol Immunology BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to vaccination with three doses of inactivated SARS-CoV-2 vaccine were followed in a cohort of 37 healthy adults (18–59 years old). Blood samples were collected at multiple time points and submitted to peptide array, machine learning modeling, and sequence alignment analyses, the results of which were used to generate vaccine-induced antibody-binding region (VIABR) immunosignatures (Registration number: ChiCTR2200058571). RESULTS: Antibody spectrum signals showed vaccination stimulated antibody production. Sequence alignment analyses revealed that a third vaccine dose generated a new highly represented VIABR near the A570D mutation, and the whole process of inoculation enhanced the VIABR near the N501Y mutation. In addition, the antigen conformational epitopes varied between short- and long-term samples. The amino acids with the highest scores in the short-term samples were distributed primarily in the receptor binding domain (RBD) and N-terminal domain regions of spike (S) protein, while in the long-term samples (12 weeks after the 2(nd) dose), some new conformational epitopes (CEs) were localized to crevices within the head of the S protein trimer. CONCLUSION: Protective antigenic epitopes were revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine inoculation. A third dose results in a new top-10 VIABR near the A570D mutation site of S protein, and the whole process of inoculation enhanced the VIABR near the N501Y mutation, thus potentially providing protection from strains that have gained invasion and immune escape abilities through these mutation. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9397116/ /pubmed/36016943 http://dx.doi.org/10.3389/fimmu.2022.938378 Text en Copyright © 2022 Peng, Dou, Zhang, Yan, Xiong, Jiang, Ou, Tang, Yu, Zhu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Peng, Mian
Dou, Xiaowen
Zhang, Xiuming
Yan, Mingchen
Xiong, Dan
Jiang, Ruiwei
Ou, Tong
Tang, Aifa
Yu, Xiqiu
Zhu, Feiqi
Li, Weiqin
Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title_full Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title_fullStr Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title_full_unstemmed Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title_short Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
title_sort protective antigenic epitopes revealed by immunosignatures after three doses of inactivated sars-cov-2 vaccine
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397116/
https://www.ncbi.nlm.nih.gov/pubmed/36016943
http://dx.doi.org/10.3389/fimmu.2022.938378
work_keys_str_mv AT pengmian protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT douxiaowen protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT zhangxiuming protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT yanmingchen protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT xiongdan protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT jiangruiwei protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT outong protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT tangaifa protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT yuxiqiu protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT zhufeiqi protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine
AT liweiqin protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine